Synthetic Promoters in Gene Therapy: Design Approaches, Features and Applications

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2024 Dec 17

PMID 39682712

Authors

Valentin Artemyev

Anna Gubaeva

Anastasiia Iu Paremskaia

Amina A Dzhioeva

Andrei Deviatkin

Sofya G Feoktistova

Olga Mityaeva

Pavel Yu Volchkov

Affiliations

Soon will be listed here.

Abstract

Gene therapy is a promising approach to the treatment of various inherited diseases, but its development is complicated by a number of limitations of the natural promoters used. The currently used strong ubiquitous natural promoters do not allow for the specificity of expression, while natural tissue-specific promoters have lowactivity. These limitations of natural promoters can be addressed by creating new synthetic promoters that achieve high levels of tissue-specific target gene expression. This review discusses recent advances in the development of synthetic promoters that provide a more precise regulation of gene expression. Approaches to the design of synthetic promoters are reviewed, including manual design and bioinformatic methods using machine learning. Examples of successful applications of synthetic promoters in the therapy of hereditary diseases and cancer are presented, as well as prospects for their clinical use.

References

Davidoff A, Gray J, Ng C, Zhang Y, Zhou J, Spence Y . Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther. 2005; 11(6):875-88. DOI: 10.1016/j.ymthe.2004.12.022. View

Spitz F . Gene regulation at a distance: From remote enhancers to 3D regulatory ensembles. Semin Cell Dev Biol. 2016; 57:57-67. DOI: 10.1016/j.semcdb.2016.06.017. View

Emami K, Jain A, Smale S . Mechanism of synergy between TATA and initiator: synergistic binding of TFIID following a putative TFIIA-induced isomerization. Genes Dev. 1997; 11(22):3007-19. PMC: 316697. DOI: 10.1101/gad.11.22.3007. View

Le Guiner C, Stieger K, Toromanoff A, Guilbaud M, Mendes-Madeira A, Devaux M . Transgene regulation using the tetracycline-inducible TetR-KRAB system after AAV-mediated gene transfer in rodents and nonhuman primates. PLoS One. 2014; 9(9):e102538. PMC: 4172479. DOI: 10.1371/journal.pone.0102538. View

Seo E, Choi Y, Shin Y, Kim D, Lee J . Design of synthetic promoters for cyanobacteria with generative deep-learning model. Nucleic Acids Res. 2023; 51(13):7071-7082. PMC: 10359606. DOI: 10.1093/nar/gkad451. View

Wu M, Nissim L, Stupp D, Pery E, Binder-Nissim A, Weisinger K . A high-throughput screening and computation platform for identifying synthetic promoters with enhanced cell-state specificity (SPECS). Nat Commun. 2019; 10(1):2880. PMC: 6599391. DOI: 10.1038/s41467-019-10912-8. View

Forrest A, Kawaji H, Rehli M, Baillie J, de Hoon M, Haberle V . A promoter-level mammalian expression atlas. Nature. 2014; 507(7493):462-70. PMC: 4529748. DOI: 10.1038/nature13182. View

Hernandez-Garcia C, Finer J . Identification and validation of promoters and cis-acting regulatory elements. Plant Sci. 2014; 217-218:109-19. DOI: 10.1016/j.plantsci.2013.12.007. View

Haberle V, Stark A . Eukaryotic core promoters and the functional basis of transcription initiation. Nat Rev Mol Cell Biol. 2018; 19(10):621-637. PMC: 6205604. DOI: 10.1038/s41580-018-0028-8. View

10.

Qiao H, Zhang S, Xue T, Wang J, Wang B . iPro-GAN: A novel model based on generative adversarial learning for identifying promoters and their strength. Comput Methods Programs Biomed. 2022; 215:106625. DOI: 10.1016/j.cmpb.2022.106625. View

11.

Burdett T, Nuseibeh S . Changing trends in the development of AAV-based gene therapies: a meta-analysis of past and present therapies. Gene Ther. 2022; 30(3-4):323-335. DOI: 10.1038/s41434-022-00363-0. View

12.

Ye G, Budzynski E, Sonnentag P, Nork T, Sheibani N, Gurel Z . Cone-Specific Promoters for Gene Therapy of Achromatopsia and Other Retinal Diseases. Hum Gene Ther. 2015; 27(1):72-82. PMC: 4741229. DOI: 10.1089/hum.2015.130. View

13.

Graybuck L, Daigle T, Sedeno-Cortes A, Walker M, Kalmbach B, Lenz G . Enhancer viruses for combinatorial cell-subclass-specific labeling. Neuron. 2021; 109(9):1449-1464.e13. PMC: 8610077. DOI: 10.1016/j.neuron.2021.03.011. View

14.

Ho S, Yang Y . Identifying and engineering promoters for high level and sustainable therapeutic recombinant protein production in cultured mammalian cells. Biotechnol Lett. 2014; 36(8):1569-79. DOI: 10.1007/s10529-014-1523-4. View

15.

Hulliger E, Hostettler S, Kleinlogel S . Empowering Retinal Gene Therapy with a Specific Promoter for Human Rod and Cone ON-Bipolar Cells. Mol Ther Methods Clin Dev. 2020; 17:505-519. PMC: 7114634. DOI: 10.1016/j.omtm.2020.03.003. View

16.

Simpson E, Korecki A, Fornes O, McGill T, Cueva-Vargas J, Agostinone J . New MiniPromoter Ple345 (NEFL) Drives Strong and Specific Expression in Retinal Ganglion Cells of Mouse and Primate Retina. Hum Gene Ther. 2018; 30(3):257-272. PMC: 6437624. DOI: 10.1089/hum.2018.118. View

17.

Lagali P, Balya D, Awatramani G, Munch T, Kim D, Busskamp V . Light-activated channels targeted to ON bipolar cells restore visual function in retinal degeneration. Nat Neurosci. 2008; 11(6):667-75. DOI: 10.1038/nn.2117. View

18.

Li X, Eastman E, Schwartz R, Draghia-Akli R . Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat Biotechnol. 1999; 17(3):241-5. DOI: 10.1038/6981. View

19.

Pucci F, Rickelt S, Newton A, Garris C, Nunes E, Evavold C . PF4 Promotes Platelet Production and Lung Cancer Growth. Cell Rep. 2016; 17(7):1764-1772. PMC: 5108525. DOI: 10.1016/j.celrep.2016.10.031. View

20.

Pavlou M, Schon C, Occelli L, Rossi A, Meumann N, Boyd R . Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders. EMBO Mol Med. 2021; 13(4):e13392. PMC: 8033523. DOI: 10.15252/emmm.202013392. View